Biological Products, (No Diagnostic Substances) · DE · CIK 1806310
Develops AAV-based gene therapies for severe monogenic central nervous system diseases
Comparable business profile · signals at a glance
In the 90 days to Feb 4, 2026: 3 sold $4.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 4, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 1,655 | $4.52 | $7K |
| Jan 26, 2026 | Nolan Sean P.Chief Executive Officer | Sell | 41,312 | $4.61 | $190K |
| Jan 26, 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 26,918 | $4.61 | $124K |
| Jan 26, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 23,849 | $4.61 | $110K |
| Jan 23, 2026 | Nolan Sean P.Chief Executive Officer | Sell | 136,789 | $4.75 | $650K |
| Jan 23, 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 89,132 | $4.75 | $423K |
| Jan 23, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 78,968 | $4.75 | $375K |
| Jan 12, 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 200,000 | $4.71 | $942K |
| Dec 1, 2025 | Nagendran SukumarPresident and Head of R&D | Sell | 260,047 | $4.51 | $1.2M |
| Nov 28, 2025 | Nagendran SukumarPresident and Head of R&D | Sell | 110,125 | $4.75 | $523K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.